Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices.

Lee F, Gottsch H, Ellis WJ, True LD, Lin DW, Wright JL.

Adv Urol. 2013;2013:471234. doi: 10.1155/2013/471234.

2.

Optimizing patient selection for prostate monotherapy.

Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):673-7.

PMID:
11172948
3.

Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

King CR, McNeal JE, Gill H, Presti JC Jr.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):386-91.

PMID:
15145152
4.

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE.

BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x.

5.

Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.

Chun FK, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currlin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI.

BJU Int. 2006 Aug;98(2):329-34.

6.

Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy.

Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, Jeong H, Byun SS, Lee HJ, Choe G, Lee SE.

World J Urol. 2009 Apr;27(2):271-6. doi: 10.1007/s00345-008-0343-3.

PMID:
19020885
7.

Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis.

Winters BR, Wright JL, Holt SK, Lin DW, Ellis WJ, Dalkin BL, Schade GR.

Urology. 2016 Oct;96:148-155. doi: 10.1016/j.urology.2016.04.058.

PMID:
27313123
8.
9.

A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?

Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja GP, Shalhav AL, Zorn KC.

J Urol. 2008 Dec;180(6):2436-40. doi: 10.1016/j.juro.2008.08.027.

PMID:
18930486
10.

Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.

Tilki D, Schlenker B, John M, Buchner A, Stanislaus P, Gratzke C, Karl A, Tan GY, Ergün S, Tewari AK, Stief CG, Seitz M, Reich O.

Urol Oncol. 2011 Sep-Oct;29(5):508-14. doi: 10.1016/j.urolonc.2009.07.003.

PMID:
19837614
11.

Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.

Krane LS, Menon M, Kaul SA, Siddiqui SA, Wambi C, Peabody JO, Agarwal PK.

Urol Oncol. 2011 Jul-Aug;29(4):372-7. doi: 10.1016/j.urolonc.2009.04.018.

PMID:
19576796
12.

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, Haese A, Heinzer H, McCormack M, Huland H, Graefen M, Karakiewicz PI.

Eur Urol. 2006 May;49(5):820-6.

PMID:
16439050
13.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x.

14.

Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer.

Fu Q, Moul JW, Bañez LL, Sun L, Mouraviev V, Xie D, Polascik TJ.

Med Oncol. 2012 Dec;29(5):3339-44. doi: 10.1007/s12032-012-0270-4.

PMID:
22688447
15.
16.

Correlation between upgrading of prostate biopsy and biochemical failure and unfavorable pathology after radical prostatectomy.

Ozden C, Oztekin CV, Ugurlu O, Gokkaya S, Yaris M, Memis A.

Urol Int. 2009;83(2):146-50. doi: 10.1159/000230014.

PMID:
19752607
17.

Prostate cancer volume at biopsy predicts clinically significant upgrading.

Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA.

J Urol. 2008 Mar;179(3):896-900; discussion 900. doi: 10.1016/j.juro.2007.10.060.

PMID:
18207180
18.

Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.

Mehta V, Rycyna K, Baesens BM, Barkan GA, Paner GP, Flanigan RC, Wojcik EM, Venkataraman G.

Int J Clin Exp Pathol. 2012;5(6):496-502.

19.

Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.

Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, Busch C, Kyrdalen AE, Svindland A, Viset T, Halvorsen OJ.

BJU Int. 2009 Jun;103(12):1647-54. doi: 10.1111/j.1464-410X.2008.08255.x.

Items per page

Supplemental Content

Support Center